Institutional
Royalty Pharma Sub-Manager, LLC
CIK 0002081668
$172.8M
Reported AUM
4
Positions
Q1 2026
Period
2026-05-14
Filed
The Brief · Royalty Pharma Sub-Manager, LLC · Q1 2026
AI · grounded in 13F
Royalty Pharma Sub-Manager, LLC increased its position in Zenas Biopharma, Inc. BCAX by 89.06%. The fund added one new position to its portfolio. Total assets under management stood at $172,764,205 across four positions.
Portfolio · Q1 2026
Top holdings
QoQ vs Q4 2025
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CYTK | CYTOKINETICS, INC | $70.51 | -1.35% | 121.30% | 140.84% | $64.6M | 37.40% | — | HELD |
| 2 | BCAX | ZENAS BIOPHARMA, INC. | $20.00 | -2.01% | 73.91% | -15.54% | $46.7M | 27.02% | +1,125,000 | +89.1% |
| 3 | BCRX | BIOCRYST PHARMACEUTICALS INC | $8.35 | -0.71% | -23.82% | -47.83% | $36.6M | 21.19% | — | HELD |
| 4 | BHVN | BIOHAVEN LTD | $11.28 | 4.44% | -36.58% | -34.82% | $24.8M | 14.38% | — | HELD |
Source: SEC EDGAR · accession 0002081668-26-000006. 13F discloses long positions only — shorts, foreign equities, and options are excluded.